The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Inhibition of the immune response by rapamycin, a new antifungal antibiotic
Abstract
Rapamycin, a new antifungal antibiotic, was found to inhibit the immune response in rats. It totally prevented the development of two experimental immunopathies (experimental allergic encephalomyelitis (EAE) and adjuvant arthritis (AA)) and the formation of humoral (IgE-like) antibody. It was about half as potent as cyclophosphamide in inhibiting EAE. In AA and on antibody formation, rapamycin and cyclophosphamide were about equipotent, whereas methotrexate was more potent. The immunosuppressant activity of rapamycin appears to be related to inhibition of the lymphatic system.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pancreatic Islet Cell Transplantation
Sutherland, D. E. R., Matas, A. J., & Najarian, J. S. (1978) · Surgical Clinics of North America · doi:10.1016/s0039-6109(16)41489-1 · Cited by 268
Cited by
mTOR Signaling in Growth, Metabolism, and Disease
Saxton, R. A., & Sabatini, D. M. (2017) · Cell · doi:10.1016/j.cell.2017.02.004 · Cited by 7,555
mTOR at the nexus of nutrition, growth, ageing and disease
Liu, G. Y., & Sabatini, D. M. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0199-y · Cited by 2,737
How were new medicines discovered?
Swinney, D. C., & Anthony, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3480 · Cited by 1,812
Sabatini, D. M., Erdjument-Bromage, H., Lui, M., Tempst, P., & Snyder, S. H. (1994) · Cell · doi:10.1016/0092-8674(94)90570-3 · Cited by 1,509
A receptor for the immuno-suppressant FK506 is a cis–trans peptidyl-prolyl isomerase
Harding, M. W., Galat, A., Uehling, D. E., & Schreiber, S. L. (1989) · Nature · doi:10.1038/341758a0 · Cited by 1,396
Natural product discovery: past, present, and future
Katz, L., & Baltz, R. H. (2016) · Journal of Industrial Microbiology and Biotechnology · doi:10.1007/s10295-015-1723-5 · Cited by 1,144
RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1
Burnett, P. E., Barrow, R. K., Cohen, N. A., Snyder, S. H., & Sabatini, D. M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.4.1432 · Cited by 1,138
Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks
Magnuson, B., Ekim, B., & Fingar, D. C. (2012) · Biochemical Journal · doi:10.1042/bj20110892 · Cited by 1,015
Rapamycin passes the torch: a new generation of mTOR inhibitors
Benjamin, D., Colombi, M., Moroni, C., & Hall, M. N. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3531 · Cited by 989
Sehgal, S. N. (1998) · Clinical Biochemistry · doi:10.1016/s0009-9120(98)00045-9 · Cited by 663
IMMUNOPHARMACOLOGY OF RAPAMYCIN
Abraham, R. T., & Wiederrecht, G. J. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.483 · Cited by 653
mTORC1 signaling and the metabolic control of cell growth
Ben-Sahra, I., & Manning, B. D. (2017) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2017.02.012 · Cited by 644
Targeting cellular senescence with senotherapeutics: senolytics and senomorphics
Zhang, L., Pitcher, L. E., Prahalad, V., Niedernhofer, L. J., & Robbins, P. D. (2023) · The FEBS Journal · doi:10.1111/febs.16350 · Cited by 621
Dendritic cells: emerging pharmacological targets of immunosuppressive drugs
Hackstein, H., & Thomson, A. W. (2004) · Nature Reviews Immunology · doi:10.1038/nri1256 · Cited by 545
Rapalogs and mTOR inhibitors as anti-aging therapeutics
Lamming, D. W., Ye, L., Sabatini, D. M., & Baur, J. A. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64099 · Cited by 531
Twenty-five years of mTOR: Uncovering the link from nutrients to growth
Sabatini, D. M. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1716173114 · Cited by 501
Modulators of Protein–Protein Interactions
Milroy, L.-G., Grossmann, T. N., Hennig, S., Brunsveld, L., & Ottmann, C. (2014) · Chemical Reviews · doi:10.1021/cr400698c · Cited by 497
RAPAMYCIN FOR IMMUNOSUPPRESSION IN ORGAN ALLOGRAFTING
Calne, R. Y., Lim, S., Samaan, A., Collier, D. S. J., Pollard, S. G., White, D. J. G., & Thiru, S. (1989) · The Lancet · doi:10.1016/s0140-6736(89)90417-0 · Cited by 367
Mechanism of action of the immunosuppressant rapamycin
Dumont, F. J., & Su, Q. (1995) · Life Sciences · doi:10.1016/0024-3205(95)02233-3 · Cited by 358
Activity of rapamycin (AY-22,989) against transplanted tumors.
ENG, C. P., SEHGAL, S. N., & VEZINA, C. (1984) · The Journal of Antibiotics · doi:10.7164/antibiotics.37.1231 · Cited by 351
Immunosuppressive drugs: the first 50 years and a glance forward
Allison, A. C. (2000) · Immunopharmacology · doi:10.1016/s0162-3109(00)00186-7 · Cited by 350
Peptidylproline cis‐trans‐isomerases: immunophilins
GALAT, A. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb18189.x · Cited by 343
Translational Control in Cancer
Robichaud, N., Sonenberg, N., Ruggero, D., & Schneider, R. J. (2019) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a032896 · Cited by 302
Rapamycin is a neuroprotective treatment for traumatic brain injury
Erlich, S., Alexandrovich, A., Shohami, E., & Pinkas-Kramarski, R. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.12.003 · Cited by 295
Kahan, B. D., Podbielski, J., Napoli, K. L., Katz, S. M., Meier-Kriesche, H.-U., & Van Buren, C. T. (1998) · Transplantation · doi:10.1097/00007890-199810270-00013 · Cited by 288
Lieberthal, W., Fuhro, R., Andry, C. C., Rennke, H., Abernathy, V. E., Koh, J. S., Valeri, R., & Levine, J. S. (2001) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.2001.281.4.f693 · Cited by 270
Murgia, M. G., Jordan, S., & Kahan, B. D. (1996) · Kidney International · doi:10.1038/ki.1996.28 · Cited by 261
Hafler, D. A., Slavik, J. M., Anderson, D. E., O'Connor, K. C., De Jager, P., & Baecher‐Allan, C. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00240.x · Cited by 260
Biosynthesis of Erythromycin and Rapamycin
Staunton, J., & Wilkinson, B. (1997) · Chemical Reviews · doi:10.1021/cr9600316 · Cited by 260
Industrial natural product chemistry for drug discovery and development
Bauer, A., & Brönstrup, M. (2014) · Nat. Prod. Rep. · doi:10.1039/c3np70058e · Cited by 255
Rapamycins: Antifungal, antitumor, antiproliferative, and immunosuppressive macrolides
Morris, R. E. (1992) · Transplantation Reviews · doi:10.1016/s0955-470x(10)80014-x · Cited by 253
Rapamycin: an anti-cancer immunosuppressant?
Law, B. K. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2004.09.009 · Cited by 252
Roberts, M. D., McCarthy, J. J., Hornberger, T. A., Phillips, S. M., Mackey, A. L., Nader, G. A., Boppart, M. D., Kavazis, A. N., Reidy, P. T., Ogasawara, R., et al. (2023) · Physiological Reviews · doi:10.1152/physrev.00039.2022 · Cited by 214
Adverse events associated with mTOR inhibitors
Pallet, N., & Legendre, C. (2013) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.752814 · Cited by 198
Translational Regulation of Autoimmune Inflammation and Lymphoma Genesis by Programmed Cell Death 4
Hilliard, A., Hilliard, B., Zheng, S.-J., Sun, H., Miwa, T., Song, W., Göke, R., & Chen, Y. H. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.11.8095 · Cited by 167
Kraig, E., Linehan, L. A., Liang, H., Romo, T. Q., Liu, Q., Wu, Y., Benavides, A. D., Curiel, T. J., Javors, M. A., Musi, N., et al. (2018) · Experimental Gerontology · doi:10.1016/j.exger.2017.12.026 · Cited by 162
The immunobiology of mTOR in autoimmunity
Suto, T., & Karonitsch, T. (2020) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.102373 · Cited by 149
Dello Russo, C., Lisi, L., Feinstein, D. L., & Navarra, P. (2013) · Glia · doi:10.1002/glia.22433 · Cited by 96
Burnett, G. L., Yang, Y. C., Aggen, J. B., Pitzen, J., Gliedt, M. K., Semko, C. M., Marquez, A., Evans, J. W., Wang, G., Won, W. S., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01658 · Cited by 72
Sofroniadou, S., & Goldsmith, D. (2011) · Drug Safety · doi:10.2165/11585040-000000000-00000 · Cited by 60
Metadata
- Authors
- Martel, R. R., Klicius, J., & Galet, S.
- Venue
- Canadian Journal of Physiology and Pharmacology
- Publisher
- Canadian Science Publishing
- Published
- 1977-02-01
- Volume
- 55
- Issue
- 1
- Pages
- 48-51
- ISSN
- 0008-4212 (ISSN-L)
- 1205-7541
- OpenAlex
- W1976726113
- Cited by
- 463
- References
- 1
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.